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Association of polygenic score for major depression with response to 
lithium in patients with bipolar disorder 
Azmeraw T. Amare 1,2 et al. 
Abstract 
Lithium is a first-line medication for bipolar disorder (BD), but only one in three patients respond 
optimally to the drug.  Since evidence shows a strong clinical and genetic overlap between depression 
and bipolar disorder, we investigated whether a polygenic susceptibility to major depression is 
associated with response to lithium treatment in patients with BD. Weighted polygenic scores (PGSs) 
were computed for major depression (MD) at different GWAS p value thresholds using genetic data 
obtained from 2586 bipolar patients who received lithium treatment and took part in the Consortium 
on Lithium Genetics (ConLi+Gen) study. Summary statistics from genome-wide association studies in 
MD (135,458 cases and 344,901 controls) from the Psychiatric Genomics Consortium (PGC) were used 
for PGS weighting. Response to lithium treatment was defined by continuous scores and categorical 
outcome (responders versus non-responders) using measurements on the Alda scale. Associations 
between PGSs of MD and lithium treatment response were assessed using a linear and binary logistic 
regression modeling for the continuous and categorical outcomes, respectively. The analysis was 
performed for the entire cohort, and for European and Asian sub-samples. The PGSs for MD were 
significantly associated with lithium treatment response in multi-ethnic, European or Asian 
populations, at various p value thresholds. Bipolar patients with a low polygenic load for MD were 
more likely to respond well to lithium, compared to those patients with high polygenic load [lowest vs 
highest PGS quartiles, multi-ethnic sample: OR = 1.54 (95% CI: 1.18–2.01) and European sample: OR = 
1.75 (95% CI: 1.30–2.36)]. While our analysis in the Asian sample found equivalent effect size in the 
same direction: OR = 1.71 (95% CI: 0.61–4.90), this was not statistically significant. Using PGS decile 
comparison, we found a similar trend of association between a high genetic loading for MD and lower 
response to lithium. Our findings underscore the genetic contribution to lithium response in BD and 
support the emerging concept of a lithium-responsive biotype in BD. 
 
Introduction 
Bipolar disorder (BD) is a chronic and severe psychiatric illness characterized by episodic, abnormal 
manic and depressive mood states. An estimated 48.8 million people are affected by BD globally [1]. 
The disorder accounts for 9.9 million years of life lived with disability worldwide, and substantially 
increases all-cause mortality and risk of suicide [1, 2]. Amongst available treatment options, lithium is 
regarded as a gold standard by several clinical guidelines [3, 4]. Lithium uniquely protects against both 
manic and depressive illness phases, has demonstrated protective effects against suicide [5–7], and is 
particularly effective in preventing rehospitalization [8]. However, not all patients with BD fully benefit 
from lithium and only about 30% show full response to the drug [5–7]. In current psychiatric practice, 
no biological or clinical markers exist that could reliably predict responsiveness to lithium [9], and 
prescribing cannot be targeted to patients who benefit most while avoiding side effects and sub-
optimal treatment for poor 
responders [10–13].   
 
In order to develop objective response markers and to move forward towards personalized prescribing 
of lithium for BD patients, a better understanding of the biological mechanisms underlying lithium 
response is urgently required. Recent genome-wide association studies (GWAS) carried out by our 
International Consortium on Lithium Genetics (ConLi+Gen) [5] and others [14, 15] have indicated that 
genetic variation could be an important mediator of response to long-term lithium treatment 
response in BD patients. In addition, we have recently demonstrated that high genetic loading for 
schizophrenia (SCZ) risk variants in people with BD decreases the likelihood of favorable response to 
lithium [16], suggesting that polygenic score (PGS) analysis of mental and physical traits could yield 
important information on the genetic architecture of BD phenotypes [17–19].  
BD and MD show 47% genetic overlap [20–22], and shared risk genes and biological pathways have 
been described [21, 23, 24]. Lithium can be effective as an augmentation strategy in MD patients who 
have experienced an insufficient response to first-line antidepressants [25, 26] and is protective 
against further MD episodes after symptom remission has been achieved [27]. Moreover, a large 
observational study based on the Finnish registry showed that lithium is the most effective agent 
preventing rehospitalization in MD [27]. 
 
On the other hand, in BD, lithium is more effective in preventing manic than depressive episodes [28, 
29], leading to the notion that better lithium responders might be more likely to experience manic 
predominant polarity, as opposed to depressive predominant polarity [30]. In support of this view, 
one study found that excellent lithium responders were characterized by a manic but not depressive 
polarity of the index episode [31]. Another study described an episodic illness pattern of ‘mania-
depression-interval’ as a predictor for a good response, whereas a ‘depression-mania-interval’ 
predicted poorer outcomes [32]. Inter-episode residual mood symptoms, as opposed to full remission 
[6, 7, 33], a rapid cycling pattern [32, 33], and a history of mixed episodes [34, 35] have also been 
described as predictors of poor response. On the background of these complex interactions between 
BD, MD, and lithium treatment, we asked whether BD patients with a high genetic susceptibility for 
major depression, expressed by their PGS, would respond better or worse to lithium than BD patients 
with a low genetic loading [36]. 
 
Methods and materials 
Discovery GWAS summary dataset 
The polygenic score for this study was computed using individual genetic data from the International 
Consortiumon Lithium Genetics (ConLi+Gen) [5], and GWAS summary statistics for MD from the 
Psychiatric Genomics Consortium (PGC) [36]. 
 
The summary GWAS for MD was produced from a meta-analysis of 9.6 million SNPs (PGC; 
http://www.med. unc.edu/pgc/), obtained from 7 cohorts (deCODE, Generation Scotland, GERA, 
iPSYCH, UK Biobank, PGC29 and 23andMe) containing 135,458 MD cases and 344,901 healthy controls 
[36]. 
 
Target study sample 
For the PGS analysis, clinical data on lithium treatment response and genetic information were 
obtained from the International Consortium on Lithium Genetics (ConLi +Gen; www.ConLiGen.org) for 
n=2586 patients, including 23 patients in the replication sample [3, 5, 16]. A series of quality control 
procedures were implemented on the genotype data before and after imputation as described below. 
 
Target outcome 
Lithium treatment response was assessed using the validated “Retrospective Criteria of Long-Term 
Treatment Response in Research Subjects with Bipolar Disorder” scale, also known as the Alda scale 
[7, 37, 38]. This scale quantifies symptom improvement over the course of treatment (A score, range 
0–10), which is then weighted against five criteria (B score) that assess the quality of evidence for the 
response score [5], to arrive at a total Alda score. For dichotomized assessment of treatment response, 
patients with a total score of 7 or higher were categorized as “good responders”, and the remainder 
were categorized as poor responders [5, 38]. For continuous assessment of treatment response, Alda 
A scores were used [39]. In addition to the Alda scale scores, information on covariates such as age 
and gender was collected, as described in detail elsewhere [5].  
 
Genotyping and quality control 
The genome-wide genotypes, as well as clinical and demographic data, were collected by 22 
participating sites. Quality control (QC) procedures were implemented on the genotype data using 
PLINK, version 1.09 prior to imputation [40]. Samples with low genotype rates <95%, sex 
inconsistencies (based on X-chromosome heterozygosity), and one of a pair of genetically related 
individuals were excluded. SNPs were excluded based on the following criteria: a poor genotyping rate 
(<95%), strand ambiguity (A/T and C/G SNPs), a low minor allele frequency (MAF < 1%), or those 
deviated from genotype frequency expectations under the Hardy–Weinberg Equilibrium (p < 10–6). 
 
Imputation 
The genotype data passing QC were imputed on the Michigan server [41] 
(https://imputationserver.sph.umich.edu) separately for each genotype platform using reference 
data from the 1000 Genomes Project Phase 3 (Version 5). The European reference panel was used for 
all the samples except for those from Japan and Taiwan, for which an East Asian reference population 
data was used. After excluding low-frequency SNPs (MAF < 10%); low-quality variants (imputation 
INFO < 0.9); and indels, the imputed dosages were converted to best-guess genotypes. The 
subsequent polygenic analyses were performed using these best-guess genotypes. 
 
Statistical analyses 
Polygenic score (PGS) association analysis PGSs were calculated using the approach previously 
described by the International Schizophrenia Consortium [42]. Prior to the PGS computation, 
independent SNPs were identified through a clumping procedure. Quality controlled SNPs were 
clumped for linkage disequilibrium based on GWAS association p value informed clumping at r2 = 0.1 
within a 250 kilobase window to create an SNPset in linkage equilibrium using PLINK software, version 
1.09 run on Linux (plink --clump-p1 1 --clump-p2 1 --clump-r2 0.1 --clump-kb 250). PGSs of MD were 
calculated for each patient in the ConLi+Gen sample at ten p value thresholds (<1 × 10−4, <1×10− 3, 
<0.01, <0.05, <0.1, <0.2, <0.3, <0.4, <0.5, <1). For a patient, a PGS was calculated at each p value 
threshold (PT) as the sum of allelic counts (from 0 to 2) for the reference alleles across independent 
SNPs on a genome-wide scale weighted by their effect sizes estimated as beta or log10 (odds ratio), 
obtained from previously published GWASs of MD [36]. Once the PGSs were constructed, a binary 
logistic regression model was applied for the binary outcome (lithium response versus non-response) 
and a linear regression modeling was implemented for the continuous outcome (Alda score on 
subscale A) to evaluate the association of the PGSs for MD with lithium treatment response at each 
PT. Using the PGS at the most optimal thresholds, we divided the study samples into quartiles and 
deciles, ranging from the lowest polygenic load (1st quartile or 1st decile) to the highest polygenic load 
(4th quartile or 10th decile). Then, we compared BP patients in the lower polygenic load quartiles (1st–
3rd quartiles or 1st–9th deciles) with patients in the highest polygenic load quartile (4th quartile or 
10th decile), to quantify the effect of MD polygenic load on lithium treatment response. The analysis 
was performed for the European sample (N = 2366), Asian sample (N = 220) and all the sample 
combined (N = 2586). Associations were considered significant at p < 0.05 after adjusting for 
covariates. 
 
The PGS association analyses were adjusted for the covariates age, gender, genotyping platform, a 
polygenic score for schizophrenia [16], a polygenic score for bipolar disorder [43], and seven principal 
components (PCs) in the combined sample or five PCs in the European sample or four PCs in the Asian 
sample. The PCs were computed using a --pca command in PLINK and then the top PCs with an 
eigenvalue of >2.0 were extracted and used as covariates to correct for population stratification. The 
analyses were performed using R for Statistical Computing and PLINK, version 1.09 for Linux [40].  
Prediction accuracy, the percentage of variance in lithium response accounted for by the PGS at each 
PT, was estimated as the variance explained by the full model including each PGS and covariates minus 
the variance explained by the model including only covariates. 
 
Sensitivity analysis 
To evaluate the robustness of our findings, we ran sensitivity analyses using GWAS summary data from 
bone traits [lumbar spine bone mineral density, femoral neck mineral density and forearm bone 
mineral density] [44] that have previously shown nonsignificant genetic correlations with psychiatric 
disorders [45]. Once we compute polygenic scores for lumbar spine bone mineral density, femoral 
neck mineral density and forearm bone mineral density, we evaluated its association with lithium 
treatment response, both continuous and categorical outcomes, in the combined sample (N = 2586). 
Each analysis was adjusted for covariates age, gender, genotyping platform, polygenic score for 
schizophrenia [16], polygenic score for bipolar disorder [43] and seven PCs. 
 
Results 
Sample characteristics and lithium treatment response rate After QC, 2586 patients (3193 before QC) 
remained for analysis. While n = 2366 were of European ancestry, the remaining (n = 220) were of 
Asian ancestry. In all, 704 patients (27.2%) responded optimally to lithium treatment (total Alda score 
≥7). Detailed sample and demographics details have been described previously [16]. Analysis of the 
correlation between the PGSs for MD and the self reported number of depressive episodes available 
for asubset of the ConLi+Gen sample (N = 1140) showed a statistically significant positive correlation, 
with estimates ranging from 0.08 to 0.12, suggesting that the PGS for MD may be an approximation 
to a more severe depressivephenotype in BD (Supplementary Fig. 1). 
 
The polygenic score for MD is inversely associated with lithium treatment response in BD 
 
Statistically significant associations were found at various p value thresholds between the PGSs for 
MD and lithium treatment response. In the combined multi-ethnic sample, the strongest association 
were found at PT < 5 × 10−2; p < 0.001, R2 = 0.8% with the continuous outcome (Alda A score) and p 
< 0.001, R2 = 0.7% with the categorical outcome (total Alda score ≥7) (Fig. 1a). 
 
In European ancestry patients, the PGS at most of the tested p value thresholds showed significant 
associations of MD PGS with lithium response across continuous and dichotomized outcomes. 
Strongest associations were found at PT < 5 × 10−2; p < 0.001, R2 = 0.7% with the continuous outcome 
and p < 0.001, R2 = 0.9% with the categorical outcome (Fig. 1b). However, in the Asian subsample, the 
association of the PGS for MD and lithium treatment response was less robust and marginal 
associations were found only with the continuous outcome at PT < 1 × 10−2 (p = 0.034, R2 = 0.85%) 
and PT < 5 × 10−2 (p = 0.042, R2 = 0.75%) (Fig. 1c). Using PRSice2 software, we found consistent results 
of association between the PGSs for MD and lithium treatment response [46] (Supplementary Fig. 2A–
C). After adjusting for multiple testing using the Bonferroni method [47], associations remained 
statistically significant in the muti-ethnic and European sample, but not in the Asian sample 
(Supplementary Table 1). Beta coefficients for all associations were negative, indicating that high 
genetic loadings for MD are associated with poorer response to lithium in BD. 
 
To further evaluate the impact of MD PGS on lithium treatment response, we divided the study 
population into quartiles and deciles based on their polygenic loading for MD. As shown in Fig. 2 and 
Table 1, BD patients who carry a lower polygenic load (1st quartile or 1st decile) for MD have higher 
odds of favorable lithium treatment response, compared to patients carrying a high polygenic load 
(4th quartile or 10th decile). In the combined sample, the odds ratio (OR) of favorable response for 
patients in the 1st quartile compared with those in the 4th quartile was 1.54 (95% CI: 1.18–2.01) and 
the OR of patients in 1st decile compared to the 10th decile was 1.49 (95% CI: 0.97–2.31). Stratified 
analysis by ethnicity found a stronger association in the European sample than the Asian sample (Table 
1, Fig. 2 & Supplementary Fig. 3). 
 
Sensitivity analysis 
To ensure the robustness of our findings, we performed a sensitivity analysis and found no significant 
association between the polygenic scores for lumbar spine bone mineral density, femoral neck mineral 
density or forearm bone mineral density and lithium treatment response in bipolar patients, p > 0.05 
for all polygenic score association tests at different p value thresholds (Supplementary Fig. 4A–C). 
 
Discussion 
Our study represents the first direct molecular evidence of an association between a genetic 
predisposition for major depression and poorer response to lithium treatment in patients with BD. 
Using PGS analyses of genetic variants related to MD, we found that BD patients with low genetic 
loading for these variants were about 1.5 times more likely to have favorable long-term outcomes 
following lithium treatment compared to BD patients with high MD genetic loading. Higher MD PGSs 
were associated with a higher number of reported life-time depressive episodes. Analyses following 
stratification of our sample into European and 
Asian ancestries indicated that these associations were particularly robust in the European subsample. 
Adjustment for the potential effects of psychiatric traits that show genetic overlap with MD (SCZ, BD), 
and sensitivity analyses with medical traits that are unrelated to psychiatric disorders [44] 
underscored the overall robustness of our findings. Our findings could form part of a genetic 
explanation for the previously described clinical observations in relation to mania, depression and 
lithium response in BD [6, 7, 28–35] and supports the notion that better lithium responsiveness could 
be associated with a ‘core’ bipolar phenotype in the Kraepelinian form of manic depression [35, 48], 
characterized by a predominant mania-depression-interval (MDI) sequence pattern [49, 50]. The fact 
that such a phenotype is complex and difficult to clinically identify is exemplified by the lack of meta-
analytic evidence for a more straightforward association between lithium response and mania over 
depression dominance in BD [50]. 
 
Similarly, previous family studies found no association between a family psychiatric history of MD and 
poorer lithium response in BD [51]. Together with the previously reported inverse association of 
lithium response and schizophrenia PGS [16], in the same cohort, our finding suggests that the 
presence of psychiatric co-morbid genetic traits in BD diminishes the likelihood of optimal treatment 
response to lithium. Given the substantial overlap between schizophrenia- and MD risk alleles [43], 
the possibility that these effects are driven by similar molecular mechanisms warrants further 
clarification in future studies. 
 
  
 
In addition to its effects in BD, lithium’s effectiveness as an adjunct antidepressant treatment for 
people with treatment resistant MD is well established [52–58], and lithium is a first line treatment 
for BD type 2 that shows a substantial genetic overlap with MD [59]. Therefore, our finding raises 
the intriguing possibility that lithium possesses specific antidepressant mechanisms of action that 
are different from the mechanisms conferring long-term treatment response in BD. 
 
 
 
 
Our finding of a more robust effect of the MD PGS association with lithium response in European 
compared to Asian patients is interesting but needs to be interpreted with caution. First, our Asian 
subsample was small (n = 220) and may not have been powered sufficiently to detect more 
consistent effects. Second, the polygenic basis of MD in East Asian and European populations is only 
partially shared with reported trans-ancestry genetic correlation of 0.33–0.41 [60]. The projection of 
MD risk alleles obtained from the global PGC study onto the Asian ConLi+Gen cohort for PGS analysis 
may, therefore, be 
less precise and underestimate the true MD PGS effect. It is notable that ethnic differences with 
regards to lithium response have not been studied extensively and are not supported by a smaller 
previous study [61]. 
 
The main limitation of our study is that PGSs for MD explain only a small proportion of the variance 
in lithium treatment response (<1%), and on their own have no utility as clinical tests. However, 
since we detected significant effects in our relatively small sample, it is likely that in the future 
increased sample sizes will further improve the predictive power of PGSs [62]. Further, the current 
version of the Alda scale assesses only overall lithium efficacy but not effects specific to 
predominant illness polarity or episode 
sequence pattern. Availability and incorporation of such information would have refined our results. 
While our findings, in isolation, are not yet ripe for clinical applications, they could serve as a 
component of multimodal prediction models incorporating clinical and other biological data. The 
development of such models and the demonstration of their potential clinical utility in prospective 
study designs are beyond the scope of the current investigation but need to be attempted to 
translate our research findings 
into actionable clinical applications. 
 
In conclusion, we demonstrated that high genetic loadings for MD are predictive of unfavorable 
long-term 
response to lithium in patients with BD. Our study underscores the potential of PGS analysis to 
contribute to predictive models for medication response in psychiatry.  The results of our study 
support clinical observations that have pointed to better lithium responsiveness in a BD subtype 
characterized by lower psychiatric co-morbidity and more dominant mania-related clinical features. 
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